For the year ending 2025-12-31, OCGN had -$39,934K decrease in cash & cash equivalents over the period. -$57,149K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -67,846 |
| Depreciation and amortization expense | 2,389 |
| Amortization of debt issuance costs | 1,362 |
| Non-cash interest expense | 100 |
| Non-cash lease expense | 1,270 |
| Non-cash expense (income) from collaborative arrangements, net | 2,462 |
| Stock-based compensation expense | 7,707 |
| Other | -1,039 |
| Prepaid expenses and other current assets | 2,607 |
| Accounts payable and accrued expenses | 3,311 |
| Lease obligations | -1,227 |
| Net cash used in operating activities | -56,964 |
| Purchases of property and equipment | 185 |
| Payment of security deposits | 126 |
| Net cash (used in) provided by investing activities | -311 |
| Proceeds from issuance of common stock | 19,854 |
| Payment of equity issuance costs | 1,526 |
| Proceeds from issuance of debt | 0 |
| Payments of debt issuance costs | 0 |
| Payment of eb-5 loan | 1,000 |
| Net cash provided by financing activities | 17,328 |
| Effect of changes in exchange rate on cash and restricted cash | 13 |
| Net (decrease) increase in cash and restricted cash | -39,934 |
| Cash and restricted cash at beginning of period | 58,821 |
| Cash and restricted cash at end of period | 18,887 |
Ocugen, Inc. (OCGN)
Ocugen, Inc. (OCGN)